Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial

ConclusionsPharmacokinetic similarity between BAT2206 and ustekinumab (USA or European Union sourced) was confirmed. The three groups had similar safety profiles, and the investigational drugs were well tolerated by subjects.Clinical Trial RegistrationThis study was registered with ClinicalTrials.gov (NCT04371185).
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research